A systematic review of the evidence of the burden of bipolar disorder in Europe
2009

The Burden of Bipolar Disorder in Europe

publication Evidence: moderate

Author Information

Author(s): Fajutrao Liberty, Locklear Julie, Priaulx Jennifer, Heyes Anne

Primary Institution: AstraZeneca R&D, Södertälje, Sweden

Hypothesis

What is the epidemiological, clinical, and economic burden of bipolar disorder in Europe?

Conclusion

Bipolar disorder is a major and underestimated health problem in Europe, significantly impacting economic burden due to comorbidities, suicide, and unemployment.

Supporting Evidence

  • Data from the UK, Germany, and Italy indicated a prevalence of bipolar disorder of ~1%.
  • A misdiagnosis rate of 70% was reported from Spain.
  • Attempted suicide rates varied between 21%–54%.
  • In the UK, the estimated rate of premature mortality of patients with bipolar I disorder was 18%.
  • 70% of patients in Germany were underemployed, and 72% received disability payments.
  • The estimated UK national cost of bipolar disorder was £4.59 billion.

Takeaway

Bipolar disorder affects about 1% of people in Europe, and it costs a lot of money because many people with it struggle to work and often need hospital care.

Methodology

A systematic review of publications from the last 10 years relating to the burden of bipolar disorder, including studies on epidemiology, patient-related issues, and costs.

Potential Biases

Potential bias due to the focus on electronic databases and language selection criteria.

Limitations

The review is limited by the scarcity of data and methodological challenges in the studies included.

Participant Demographics

The review included studies from various European countries, primarily focusing on general populations.

Digital Object Identifier (DOI)

10.1186/1745-0179-5-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication